Category: 2089292-88-4

On June 24, 2021, Cotesta, Simona; Gerspacher, Marc; Leblanc, Catherine; Liu, Bo; Lorthiois, Edwige Liliane Jeanne; Machauer, Rainier; Mah, Robert; Mura, Christophe; Rigollier, Pascal; Schneider, Nadine; Stutz, Stefan; Vaupel, Andrea; Warin, Nicolas; Wilcken, Rainer published a patent.Formula: C7H6BrN3 The title of the patent was Pyrazolyl derivatives useful as anti-cancer agents. And the patent contained the following:

Pyrazolyl derivatives of formula I [A = cycloalkyl, heterocyclyl, aryl, heteroaryl, etc.; B = aryl, heteroaryl, etc.; C = H, alkyl, cycloalkyl, fluoroalkyl, CN, CH2OH, etc.; L = spirocycloalkyl, etc.; G = COCH=CH2, COCCH, SO2-alkylene, etc.] or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, are prepared as anticancer agents. Thus, (R)-II was prepared, and had IC50 value of 0.017μM in KRASG12C covalent competition assay. The experimental process involved the reaction of 5-Bromo-2-methyl-2H-pyrazolo[3,4-c]pyridine(cas: 2089292-88-4).Formula: C7H6BrN3

The Article related to pyrazolyl derivative preparation anticancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Formula: C7H6BrN3

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On June 24, 2021, Liu, Bo; Cotesta, Simona; Gerspacher, Marc; Leblanc, Catherine; Lorthiois, Edwige Liliane Jeanne; Machauer, Rainer; Mah, Robert; Mura, Christophe; Rigollier, Pascal; Schneider, Nadine; Stutz, Stefan; Vaupel, Andrea; Warin, Nicolas; Wilcken, Rainer published a patent.Product Details of 2089292-88-4 The title of the patent was Pyrazole derivatives as anti-cancer agents and preparation. And the patent contained the following:

The invention relates compounds of formula I, us as anti-cancer agents in the ability to inhibit KRASG12C and their preparation Compound I, wherein A is (un)substituted C5-7, (un)substituted C5-10, (un)substituted 5- to 7-membered unsaturated heterocyclyl containing one carbon-carbon double bond and one oxygen, etc.; B selected from the group of B1 and B2; B1 is (un)substituted C6-10 with 1, 2, 3 and 4 RBa; B2 is 6- to 13-membered heteroaryl containing 1, 2 and 3 nitrogen atoms and is (un)substituted 1, 2, 3 and 4 RBb; each RBa is independently hydroxy, C1-4 alkyl, halo, etc.; each RBb is independently C1-4 alkyl; cyclopropyl, halo, etc.; C is hydrogen, C1-3 alkyl, C3-5 cycloalkyl, etc.; L is (un)substituted 2-azaspiro[3.3]heptanyl, (un)substituted 2-azaspiro[3.4]heptanyl, pyrrolidine, etc.; D is (un)substituted prop-2-en-1-one, (un)substituted prop-2-yn-1-one, etc.; and stereoisomers, atropisomers, pharmaceutically acceptable salts, thereof, are claimed. Conmpound II was prepared using a multistep procedure (procedure given). Compound II was evaluated for KRAS G12C inhibitory activity yielding an IC50 of 0.017μM. Compounds of the invention were evaluated for KRAS G12C inhibitory activity (data given). The experimental process involved the reaction of 5-Bromo-2-methyl-2H-pyrazolo[3,4-c]pyridine(cas: 2089292-88-4).Product Details of 2089292-88-4

The Article related to pyrazole preparation cancer kras inhibition, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Product Details of 2089292-88-4

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On January 6, 2022, Reynolds, Dominic; Seiler, Michael W.; Agrawal, Anant A.; Vaillancourt, Frederic; Smith, Peter; Hopper, Allen T.; Prajapati, Sudeep; Vyskocil, Stepan published a patent.HPLC of Formula: 2089292-88-4 The title of the patent was Preparation of 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids for the treatment of proliferative diseases. And the patent contained the following:

The disclosure relates to the title compounds I, wherein A and B are independently (un)substituted heterocyclyl and heteroaryl; L1 and L2 are independently absent, O, CO, etc.; X and Y are independently N and CR6; R2 and R3 are independently C1-6 alkyl, halo, CN, etc.; R6 is H, halo, CN, etc.; m = 0-1; N = 0-2; and pharmaceutically acceptable salts thereof, solvates, hydrates, tautomers, and stereoisomers thereof, that modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof. Example compound II was prepared by a multistep procedure (procedure given). Compounds described herein were used to modulate RNA transcript abundance in cells (data given for representative compounds I). The experimental process involved the reaction of 5-Bromo-2-methyl-2H-pyrazolo[3,4-c]pyridine(cas: 2089292-88-4).HPLC of Formula: 2089292-88-4

The Article related to indazolyl piperidinylnaphthyridine preparation nucleic acid mrna splicing modulator antiproliferative, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.HPLC of Formula: 2089292-88-4

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics